Search results for "Cholinergic"

showing 10 items of 251 documents

Cellular Distribution and Expression of Cortical Acetylcholine Receptors in Aging and Alzheimer's Disease

1991

Ligand binding studies show marked reductions of nicotinic, but not of muscarinic binding sites in Alzheimer's disease. Using monoclonal antibodies we studied immunohistochemically the expression of the respective receptor proteins in the frontal cortex of middle-aged (55 +/- 5 yr) controls, age-matched controls (73 +/- 6 yr), and patients with Alzheimer's disease (74 +/- 5 yr). Density of nicotinic cholinoceptive neurons was 8000/mm3 for middle-aged controls and 4000/mm3 for age-matched controls, but only 900/mm3 in Alzheimer's brains (p less than 0.0001). Densities of muscarinic cholinoceptive and of Nissl-stained neurons were not significantly different between the groups, pointing to a …

Agingmedicine.medical_specialtyCORTEXGeneral Biochemistry Genetics and Molecular BiologyHistory and Philosophy of ScienceAlzheimer DiseaseInternal medicineMuscarinic acetylcholine receptormedicineHumansReceptors CholinergicBinding siteReceptorNEURONSAcetylcholine receptorCerebral CortexChemistryGeneral Neurosciencemedicine.diseaseCHOLINOCEPTORSCortex (botany)medicine.anatomical_structureEndocrinologyNicotinic agonistCerebral cortexAlzheimer's disease
researchProduct

ADAM-10 over-expression increases cortical synaptogenesis.

2006

Cortical cholinergic, glutamatergic and GABAergic terminals become upregulated during early stages of the transgenic amyloid pathology. Abundant evidence suggests that sAPP alpha, the product of the non-amyloidogenic alpha-secretase pathway, is neurotrophic both in vitro and when exogenously applied in vivo. The disintegrin metalloprotease ADAM-10 has been shown to have alpha-secretase activity in vivo. To determine whether sAPP alpha has an endogenous biological influence on cortical presynaptic boutons in vivo, we quantified cortical cholinergic, glutamatergic and GABAergic presynaptic bouton densities in either ADAM-10 moderate expressing (ADAM-10 mo) transgenic mice, which moderately ov…

Agingmedicine.medical_specialtySynaptogenesisPresynaptic TerminalsAlpha (ethology)Mice TransgenicBiologyReceptors Metabotropic GlutamateGlutamatergicADAM10 ProteinMiceReceptors GABAInternal medicinemedicineAnimalsHumansReceptors CholinergicCerebral CortexGeneral NeuroscienceGene Expression Regulation DevelopmentalMembrane Proteinscarbohydrates (lipids)ADAM Proteinsmedicine.anatomical_structureEndocrinologyCerebral cortexSynaptic plasticitySynapsesbiology.proteinGABAergicCholinergicCattleNeurology (clinical)Geriatrics and GerontologyAmyloid Precursor Protein SecretasesDevelopmental BiologyNeurotrophinNeurobiology of aging
researchProduct

Behavioral effects of different enriched environments in mice treated with the cholinergic agonist PNU-282987.

2013

Abstract Environmental enrichment is an experimental model in which rodents are housed in complex environments that favor lower levels of anxiety-like behavior. PNU-282987 (PNU) is a α7 nicotinic acetylcholine receptor agonist with beneficial effects on learning though its effects on anxiety are unclear. Our main aim was to carry out a study of its effects in NMRI ( n  = 96) mice reared in different environments: environmental enrichment (EE), Marlau™ cages (MC) and standard environment (SE). After a 4-month period, mice received acute treatment of PNU (2.5, 5 and 10 mg/kg) and were evaluated in the elevated plus-maze (EPM) and hole-board (HB). In the EPM, both EE and MC reared mice showed …

AgonistMalemedicine.medical_specialtyElevated plus mazealpha7 Nicotinic Acetylcholine Receptormedicine.drug_classAnxietyEnvironmentMotor ActivityDevelopmental psychologyBehavioral NeuroscienceBridged Bicyclo CompoundsMiceα7 nicotinic acetylcholine receptorInternal medicinemedicineAnimalsNicotinic AgonistsBeneficial effectsEnvironmental enrichmentBehavior AnimalExperimental modelGeneral MedicineNicotinic agonistEndocrinologyBenzamidesExploratory BehaviorCholinergicAnimal Science and ZoologyPsychologyInjections IntraperitonealBehavioural processes
researchProduct

Interaction between cannabinoid CB1 receptors and endogenous ATP in the control of spontaneous mechanical activity in mouse ileum

2009

Background and purpose Although it is well accepted that cannabinoids modulate intestinal motility by reducing cholinergic neurotransmission mediated by CB(1) receptors, it is not known whether the endocannabinoids are involved in more complex circuits and if they interact with other systems. The aim of the present study was to examine possible interactions between cannabinoid CB(1) receptors and purines in the control of spontaneous contractility of longitudinal muscle in mouse ileum. Experimental approach The mechanical activity of longitudinally oriented ileal segments from mice was recorded as isometric contractions. Key results The selective CB(1) receptor agonist, N-(2-chloroethyl)5,8…

AgonistMalemedicine.medical_specialtyP2Y receptormedicine.drug_classmedicine.medical_treatmentCB(1) receptorArachidonic AcidsP2 receptorBiologyIn Vitro TechniquesSettore BIO/09 - FisiologiaMiceAdenosine TriphosphateReceptor Cannabinoid CB1IleumInternal medicinemedicineAnimalsReceptorP2X receptors: enteric nervous systemcholinergic transmissionPharmacologypurineDose-Response Relationship DrugPurinergic receptorcannabinoidReceptor antagonistAdenosine receptorResearch PapersBiomechanical PhenomenaATPMice Inbred C57BLEndocrinologyCannabinoidGastrointestinal MotilityProtein Binding
researchProduct

Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease.

2000

Impairment of the central cholinergic system has a pivotal role in the cognitive decline observed in patients with Alzheimer’s disease (AD). One of the most prominent cholinergic deficits is the reduced number of nicotinic acetylcholine receptors (nAChR) in the brain. Since these receptors are important for memory and learning, enhancing nicotinic neurotransmission is a promising treatment strategy for AD. The two most common approaches to correcting these cholinergic deficits are to increase the synaptic availability of acetylcholine (ACh) by inhibiting acetylcholinesterase (AChE), or to mimic the effects of ACh (nicotinic agonists) by acting directly on nicotinic receptors. Clinical studi…

Agonistmedicine.drug_classGalantamineCognitive NeuroscienceAllosteric regulationCholinergic AgentsPharmacologyReceptors NicotinicAcetylcholinesteraseSynaptic TransmissionPsychiatry and Mental healthchemistry.chemical_compoundNicotinic agonistchemistryAlzheimer DiseaseGalantaminemedicineCholinergicHumansGeriatrics and GerontologyCognitive declineNeuroscienceAcetylcholinemedicine.drugDementia and geriatric cognitive disorders
researchProduct

Characterization of sensory neurotransmission and its inhibition via alpha 2B-adrenoceptors and via non-alpha 2-receptors in rabbit iris.

1993

To find out whether, and which type of, adrenoceptors mediate prejunctional inhibition of sensory neurotransmitter release from trigeminal fibres, the modulation of twitch response to electrical field stimulation on rabbit isolated iris was investigated. Evoked iris sphincter contractions consisted of a minor fast cholinergic and a large slow component. The latter was unaffected by atropine and guanethidine, hence nonadrenergic noncholinergic in nature (NANC), but nearly completely abolished by capsaicin pretreatment and by the neurokinin receptor antagonist spantide. The response was probably not mediated by NK2 receptors as SR 48,968, an NK2 selective nonpeptide antagonist, failed to redu…

Agonistmedicine.medical_specialtymedicine.drug_classRauwolscineOxymetazolineOxymetazolineImidazoline receptorIrisSubstance PKininsNeurotransmissionIn Vitro TechniquesSubstance Pchemistry.chemical_compoundInternal medicinemedicineAnimalsNeurons AfferentSympathomimeticsReceptorPharmacologyNeurotransmitter AgentsChemistryGeneral MedicineReceptors Adrenergic alphaReceptor antagonistElectric StimulationEndocrinologyCholinergic FibersRabbitsmedicine.drugMuscle ContractionSignal TransductionNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.

2003

Galantamine (Reminyl), an approved treatment for Alzheimer's disease (AD), is a potent allosteric potentiating ligand (APL) of human alpha 3 beta 4, alpha 4 beta 2, and alpha 6 beta 4 nicotinic receptors (nAChRs), and of the chicken/mouse chimeric alpha 7/5-hydroxytryptamine3 receptor, as was shown by whole-cell patch-clamp studies of human embryonic kidney-293 cells stably expressing a single nAChR subtype. Galantamine potentiates agonist responses of the four nAChR subtypes studied in the same window of concentrations (i.e., 0.1-1 microM), which correlates with the cerebrospinal fluid concentration of the drug at the recommended daily dosage of 16 to 24 mg. At concentrations10 microM, gal…

Agonistmedicine.medical_specialtymedicine.drug_classRecombinant Fusion ProteinsAllosteric regulationPhenylcarbamatesRivastigminePharmacologyReceptors NicotinicMiceAllosteric RegulationPiperidinesInternal medicineMuscarinic acetylcholine receptormedicineGalantamineAnimalsHumansDonepezilReceptorTrichlorfonCells CulturedPharmacologyNeuronsChemistryGalantamineLigand (biochemistry)Receptors MuscarinicEndocrinologyNicotinic agonistIndansTacrineMolecular MedicineCholinergicCarbamatesCholinesterase Inhibitorsmedicine.drugThe Journal of pharmacology and experimental therapeutics
researchProduct

β2 long-acting and anticholinergic drugs control TGF-β1-mediated neutrophilic inflammation in COPD

2012

AbstractWe quantified TGF-β1 and acetylcholine (ACh) concentrations in induced sputum supernatants (ISSs) from 18 healthy controls (HC), 22 healthy smokers (HS) and 21 COPDs. ISSs from HC, HS and COPD as well as rhTGF-β1 were also tested in neutrophil adhesion and in mAChR2, mAChR3 and ChAT expression experiments in human bronchial epithelial cells (16-HBE). Finally, we evaluated the effects of Olodaterol (a novel inhaled β2-adrenoceptor agonist) and Tiotropium Spiriva®, alone or in combination, on neutrophil adhesion and mAChRs and ChAT expression in stimulated 16-HBE. The results showed that 1) TGF-β1 and ACh concentrations are increased in ISSs from COPD in comparison to HC and HS, and T…

Agonistmedicine.medical_specialtymedicine.drug_classchemistry.chemical_compoundInternal medicineTGF-β1Anticholinergic drugMuscarinic acetylcholine receptormedicineCOPDReceptorMolecular BiologyBeta2 long actingCOPDChemistryOlodaterolTiotropium bromidemedicine.diseaserespiratory tract diseasesEndocrinologyMolecular MedicineNeutrophilic inflammationBronchoconstrictionmedicine.symptomAcetylcholinemedicine.drugBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
researchProduct

A Trisialoganglioside Containing a Sialyl α2-6 N-Acetylgalactosamine Residue Is a Cholinergic-Specific Antigen, Chol-1α1

1992

Cholinergic-specific antigens termed the Chol-1 family have been suggested to be of a ganglioside nature by Richardson et al. (J. Neurochem. 38, 1605-1614, 1982). Two molecular species of polysialogangliosides among bovine brain gangliosides were found to react with anti-Chol-1 alpha antiserum. One of them, Chol-1 alpha-a, was isolated and characterized as a trisialoganglioside containing the gangliotetraose backbone in which 1 mol of sialic acid was attached to each of the reducing end galactose, N-acetylgalactosamine and internal galactose residues, respectively. The chemical structure of Chol-1 alpha-a was determined for the first time, being as follows: IV3NeuAc III6NeuAc II3NeuAc-GgOse…

AntiserumGangliosidetechnology industry and agricultureGeneral MedicineBiologyBiochemistryN-AcetylgalactosamineSialic acidchemistry.chemical_compoundResidue (chemistry)chemistryAntigenBiochemistryGalactosepolycyclic compoundsCholinergiclipids (amino acids peptides and proteins)Molecular BiologyThe Journal of Biochemistry
researchProduct

A Methanol Extract ofBrugmansia arboreaAffects the Reinforcing and Motor Effects of Morphine and Cocaine in Mice

2013

Previous reports have shown that several of the effects of morphine, including the development of tolerance and physical withdrawal symptoms, are reduced by extracts ofBrugmansia arborea(L.) Lagerheim (Solanaceae) (B. arborea). In the present study we evaluate the action of the methanol extract ofB. arborea(7.5–60 mg/kg) on the motor and reinforcing effects of morphine (20 and 40 mg/kg) and cocaine (25 mg/kg) using the conditioned place preference (CPP) procedure. At the doses employed,B. arboreadid not affect motor activity or induce any effect on CPP. The extract partially counteracted morphine-induced motor activity and completely blocked the CPP induced by 20 mg/kg morphine. On the othe…

Article Subjectbiologybusiness.industryDopaminergiclcsh:Other systems of medicinePharmacologylcsh:RZ201-999biology.organism_classificationConditioned place preferenceComplementary and alternative medicineMechanism of actionBrugmansiaMorphinemedicineCholinergicMotor activitymedicine.symptombusinessCocaine abuseResearch Articlemedicine.drugEvidence-Based Complementary and Alternative Medicine
researchProduct